Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579083 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV
A Phase 1 study, sponsored by KBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02579083 is a Phase 1 study that has completed, run by KBio. The registered enrollment target is 38 participants.
The verdict
NCT02579083, a Phase 1 study, has completed, sponsored by KBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and pharmacokinetics of MB66, a monoclonal antibody film for vaginal application that is being developed to potentially reduce the transmission of herpes simplex virus (HSV) and human immunodeficiency virus (HIV).
Interventions
- DRUG Placebo Film
- DRUG MB66
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02579083
The ClinicalTrials.gov registry entry for NCT02579083 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KBio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Film is the first listed.
NCT02579083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02579083 about?
NCT02579083 is a clinical study titled "Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV". The purpose of this study is to assess the safety and pharmacokinetics of MB66, a monoclonal antibody film for vaginal application that is being developed to potentially reduce the transmission of herpes simplex virus (HSV) and human immunodeficiency virus (HIV).
What is the current status of trial NCT02579083?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2016-01. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02579083?
The interventions under investigation include: Placebo Film (DRUG), MB66 (DRUG).
Who is sponsoring clinical trial NCT02579083?
This trial is sponsored by KBio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.